Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.
Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
Receive JSR Life Sciences news on your RSS reader.